Related Experiment Video
Updated: Apr 24, 2026
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Relationships of COX2 and MMP12 genetic polymorphisms with chronic obstructive pulmonary disease risk: a
Xiao-Ling Yu1, Jun Zhang, Fei Zhao
1Department of Respiratory Medicine, The Fourth Affiliated Hospital of China Medical University, South Seven Road No. 102, Heping District, Shenyang, 110005, People's Republic of China, yuxiaoling1220@163.com.
Abstract:
We performed the present meta-analysis in an attempt to confirm the correlation of genetic polymorphisms in the COX2 and MMP12 genes with the susceptibility to chronic obstructive pulmonary disease (COPD). We searched English database such as PubMed, CISCOM, CINAHL, Web of Science, Google Scholar and several Chinese database for meta-analysis. There were no specific language restrictions. Two investigators systematically extracted relevant data within those included studies. Crude ORs with its corresponding 95 % CI were calculated. STATA 12.0 software was adopted for statistical analysis. The impact of COX2 and MMP12 genetic polymorphisms on the pathogenesis of COPD was investigated in the current study with a total of 10 case-control studies, which includes 1,751 COPD patients and 2,472 healthy subjects. Four common polymorphisms, including rs689466 G > A and rs20417 G > C in the COX2 gene, rs652438 A > G and rs2276109 A > G were evaluated in the MMP12 gene. Pooled OR of the present studies and results showed that the frequency of COX2 rs20417 polymorphism was prevalent in COPD patients than those of healthy subjects (C allele vs. G allele OR = 1.33, 95 % CI 1.06-1.67, P = 0.014; GC + CC vs. GG OR = 1.86, 95 % CI 1.07-3.24, P = 0.029; respectively). However, we found no significant correlation between COX2 rs689466 polymorphism and the risk of COPD (all P > 0.05). Furthermore, our meta-analysis illustrated that individuals with MMP12 rs652438 polymorphism had significantly increased risk of developing COPD (G allele vs. A allele OR = 1.62, 95 % CI 1.08-2.42, P = 0.020; AG + GG vs. AA OR = 2.14, 95 % CI 1.12-4.09, P = 0.021; respectively). Nevertheless, no positive relation was detected between MMP12 rs2276109 variant and the risk of COPD. Our meta-analysis indicates that COX2 and MMP12 genetic polymorphisms may be strongly implicated in the development of COPD, especially for the COX2 rs20417 and MMP12 rs652438 polymorphisms. Thus, COX2 and MMP12 genetic polymorphisms could potentially be utilized as helpful biomarkers for early diagnosis of COPD.
